IFI27L2

Across TCGA pan-cancer cohorts, IFI27L2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IFI27L2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IFI27L2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IFI27L2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where IFI27L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.264	1.000	.003	52	view →
LUAD	OS	Median	All	0.944	1.000	.008	18	view →
LSCC	DFS	Median	II,III,IV	0.902	0.563	.014	13	view →
PDAC	OS	Median	II,III,IV	0.875	0.751	.024	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IFI27L2–HNSC (DFS)

Open the HNSC breakdown →